Copyright©2007-2013 ChemSpider Blog
I am happy to announce that ChemSpider is a part of the Open PHACTS project. It is detailed in the following PDF file but can be summarized with the extract from the Wikipedia article I recently posted.
“Open PHACTS is an Innovative Medicines Initiative project aiming to deploy a highly innovative open standards, open access, semantic web approach to address key bottlenecks in small molecule drug discovery – disparate information sources, lack of standards and information overload. It will become an open, integrated and sustainable chemistry, biology and pharmacology knowledge resource for drug discovery. It will provide tools for a comprehensive platform of chemical, biological and pharmacological information, confederated from vast, distributed and variable data and information sources. This semantically enriched and fully interoperable platform will deliver information on small molecules and their pharmacological profiles, including pharmacokinetics and ADMET data as well as on biological targets and pathways. The proposed platform will be a widely accessible, open innovation platform that will serve EFPIA partners as well as biotech and academic drug-discovery for one of their core business activities: knowledge discovery and verification. Practicing drug-discovery scientists in both the public and the private sector will turn to this service to: – integrate data on target expression, biological pathways and pharmacology to identify the most productive points for therapeutic intervention – investigate the in vitro pharmacology and mode-of-action of novel targets to help develop screening assays for drug discovery programs – compare molecular interaction profiles to assess potential off-target effects and safety pharmacology – analyse chemical motifs against biological effects to deconvolute high content biology assays.
The Open PHACTS consortium comprises 23 European core partners, with leading experts in the fields of data mining, annotation, small molecule data storage and manipulation, target related bioinformatics, pathway annotation, protein structure analysis, massive daily in silico reasoning, chemical biology, and computational chemistry. These are: Pfizer, Universität Wien>, Technical University of Denmark, University of Hamburg, BioSolveIT GmBH, Consorci Mar Parc de Salut de Barcelona, Leiden University Medical Centre, Netherlands Bioinformatics Centre, Royal Society of Chemistry, Vrije Universiteit, Spanish National Cancer Research Centre, University of Manchester, Maastricht University, ACKnowledge, University of Santiago de Compostela, >Rheinische Friedrich-Wilhelms-Universität Bonn, AstraZeneca, GlaxoSmithKline, Laboratorios del Dr. Esteve, Novartis, Merck KGaA, Lundbeck, and Eli Lilly.”